The performance of clinical laboratory testing in the USA is regulated under the Clinical Laboratory Improvement Act of 1967 (CLIA '67) and its amendments of 1988 (CLIA '88). The act defines a clinical laboratory as 'a place where materials derived from the human body are examined for the purpose of providing information for the diagnosis, prevention or treatment of any disease or impairment of, or assessment of the health of human beings'. Under this definition some 150000 locations ranging from physicians' offices to hospital laboratories and local and national reference laboratories qualify as laboratories and are affected by the standards that are integral to the law and its amendments. The standards apply particularly to the qualifications of laboratory personnel, quality control and quality assurance. The standards are formulated around the complexity of a test and the potential to harm a patient if an incorrect result is obtained and a physician takes an inappropriate action because of it. Three categories of complexity have been defined: waived, moderately complex (with a sub-category of physicianperformed microscopy) and highly complex. Waived testing is typically the only testing performed in a physician's office although some offices also perform moderately complex testing, and an even smaller number might perform highly complex tests. There are no personnel or regulatory inspection requirements for waived testing, but requirements are defined for the other test categories.
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This article is the second of two parts, the first of which, on the structure of health care finance in the USA, appeared in the previous issue (January 1999).
Almost half of all laboratory testing in the USA is performed in hospitals, with about 30% performed in for-profit commercial laboratories and the remainder performed in physicians' offices. The range of testing performed in a hospital or commercial laboratory is such that these test sites have to meet the highly complex testing standards. Since the implementation of the CLIA '88 regulations the proportion of tests performed in physicians' offices has decreased. Much of the testing previously performed by physicians in their offices is now performed in independent (commercial) or hospital laboratories. Hospitals typically perform the tests needed for their own outpatients and inpatients, but many now offer their services to unaffiliated physicians. In the interests of efficiency and cost-benefit, hospitals often refer some of their esoteric tests to reference laboratories that specialize in that type of testing.
PAYMENT FOR LABORATORY SERVICES
In the USA hospital laboratories are financed from the hospital budget. In most hospitals the technical staff are employees of the hospital while the laboratory directors and pathologists often are not. The pathologist may be a university employee in an academic medical centre or a private contractor of his/her services in a non-academic medical centre. Medicare separates the fees that it pays for laboratory tests into two components: 'Part A' which covers the technical and administrative aspects of testing and 'Part B' which pays for physician services. If the pathologists are not employees of the hospital they are required by law to receive a fee from the hospital, out of its Part A payment, to manage the clinical laboratory. Laboratory medical staff, but not doctoral scientists, are able to charge Part B fees for certain interpretative and consultative services, and anatomic pathologists are able to charge for their professional services, such as review and interpretation of surgical pathological specimens.
Hospital administrations maintain their influence over the clinical laboratories by controlling their expense budget. Hospitals charge fees for laboratory tests performed on inpatients to payers other than Medicare and the various insurance companies whose patients are capitated. However, so little income is typically attributable to inpatient laboratory testing that most hospitals ignore it when calculating returns on investment for new equipment. The proportion of patients covered by the different health plans varies from place to place and has varied with time. For Medicare, inpatients are classified at the time of discharge according to their diagnosis, deemed, after evaluation, to be the reason for their hospitalization. The diagnoses are classified into specific Diagnosis Related Groups (DRGs) and the payment to the hospital is a single fee based on the specific DRG. All laboratory Part A charges are included in this single fee, regardless of the number of tests performed on the patient during the hospitalization. The payment will be the same for a hospitalized diabetic patient whether the physician orders one or a hundred blood glucose determinations in the course of the hospital stay. For Medicare outpatients and for patients whose care is covered by the various insurance companies, tests are billed on a fee-for-service basis, but the payment received rarely corresponds to the charge made for the test. Medicare has established its own fee schedule but also has stipulated that it must be charged the lower of its stated fee or any fee charged by the hospital for that test. Many insurance companies have also negotiated fees for both inpatient and outpatient services with individual hospitals.
Laboratory fee schedules are published annually by each Medicare carrier. A set fee is assigned to each laboratory test or procedure (for example, a test may be a blood glucose determination, while a procedure may include the technical aspects of processing and preparing a surgical pathology specimen). A national comprehensive procedure terminology (CPT) code, maintained by the American Medical Association, is assigned to each laboratory and medical/surgical test and procedure, although the actual amount of the payment may differ from state to state. All payments to physicians are calculated on a resource-based relative value scale (RBRVS) which takes into account the cognitive time (in effect, the extent of the physician's skill required) and the value of the procedure, the cost of providing it and the Ann cu« Biochem 1999: 36 cost of the physician's malpractice insurance. For outpatients, Medicare stipulates that only the laboratory performing a test may bill Medicare. Physicians may not bill Medicare for tests they send out, but a laboratory may do this, provided it performs at least 70% of all the tests sent to it.
Although Medicare only pays for the care of a portion of the total population, it has strict rules that must be adhered to by all laboratories if they are to receive any payment from a government agency. Medicare policies are frequently followed by third party insurance companies. Laboratories invariably adhere to Medicare policies as if they affect all patients. This approach recognizes the reality that having different policies for different payers would add considerable burden to the laboratory (requiring it to differentiate tests for the patients of one payer from those of another), and is also contrary to the concept of a uniform standard of care for all patients.
Medicare has recently become very aggressive in pursuing lawsuits against hospitals, reference (commercial) laboratories and individual health care providers that it believes have defrauded the government by billing for services that they did not provide, or which were provided when they were not appropriate. In the past, claims for payment for laboratory tests were seldom screened by the Medicare carriers to assess the appropriateness of the tests or their medical necessity, and almost all claims were paid without question. Medicare specifically targeted the large national reference laboratories. The magnitude of the fines, collectively of the order of $1 x 10 9 , has heightened the awareness of all laboratories of the need to adhere strictly to Medicare rules. Many hospitals were also fined for separately billing for out-patient testing when this was done within 3 days of a patient's admission to hospital. Under Medicare's rules such testing is included in the DRG payment to the hospital for management of the patient and cannot be separately charged.
Medicare has determined that only physicians can provide certain billable laboratory services. Thus, only physicians are deemed to have the necessary background to interpret certain tests properly. The pertinent tests are listed in Table  1 . Even if the tests have been performed and reviewed by a trained, doctoral-level clinical scientist, Medicare will only pay for the interpretation when this has been provided by a physician.
Medicare requires that a physician or surgeon caring for a patient specifically requests an interpretation of the results of tests before the laboratory may charge for these tests' interpretation. Medicare also requires that a consultation related to a test result outside the normal or expected range results in a written report that is included in the patient's medical record, and req uires the exercise of medical judgment by the consulting physician. Until this year, Medicare permitted the medical board, or its equivalent, of a hospital to authorize an automatic interpretation for any of these tests if they were ordered. However, after examination of the use of this comprehensive authorization in Florida, Medicare perceived that the practice led to an inappropriate increase in the number of consultations and decreed that in 1998 a consultation fee would only be paid if a physician specifically requested the consultation. Medicare has in practice made an exception to this change for protein electrophoresis and immunoelectrophoresis and has permitted hospitals to continue their standing order policies for these tests, while denying any such exceptions for all other previously authorized tests.
In addition to paying for laboratory testing, Medicare also pays for venepunctures and 24-h urine collections, but for no other urine collections. It does not pay for specimen collection for routine urinalysis, throat culture swabs, faecal occult blood specimens or finger or heel stick blood collection.
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Fee schedules for laboratory tests are published annually by each Medicare carrier. The overall Medicare fee schedule changes in a remarkably confusing and inordinately complicated manner. The trend of payments has been downwards, so that the payment for a test in 1998, even without considering the influence of inflation, is substantially less than when the approach was instituted in 1984. When adjusted for inflation, a product costing $10·00 in 1984 would be expected to cost $15·70 in 1998. Table  2 illustrates the actual changes in payment for a test whose charge was established as $10·00 in 1984.
THE APPROPRIATENESS OF TESTS
Medicare has recently instituted several new laboratory policies. Although these policies strictly apply to Medicare patients only, few institutions are capable of differentiating patients who are covered by Medicare from other patients and have consequently interpreted the requirements as applying to all patients.
Starting in 1995, the Health Care Financing Administration (HCFA), administratively responsible for the Medicare programme, took several steps that radically changed reimbursement to hospitals or laboratories that performed tests on Medicare patients who were not hospital inpatients. The intent was to reduce the government's costs for testing. These policies focused on tests performed on high-volume TABLE l. Tests/or which physicians may hil/for interpretations Haemoglobin; electrophoresis Nucleic acid probe, with electrophoresis, with examination and report Protein, total, serum; electrophoretic fractionation and quantitation Protein; Western Blot with interpretation and report, blood or other body fluid Protein; Western Blot, with interpretation and report, blood or other body fluid, immunological probe for band identification; each probe Fibrinolysin; screening Platelet; aggregation (in vitro), any agent Fluorescent antibody; screen Fluorescent antibody; titre Immunoelectrophoresis; serum, each specimen Immunoelectrophoresis; other fluids (e.g., urine) with concentration, each specimen Immunoelectrophoresis; crossed (two-dimensional assay) Immunofixation electrophoresis Dark field examination, any source (e.g., penile, vaginal, oral, skin); includes specimen collection Smear, primary source, with interpretation; special stain for inclusion bodies or intracellular parasites (e.g., malaria, kala azar, herpes) Protein analysis of tissue by Western Blot, with interpretation and report Protein analysis of tissue by Western Blot, immunological probe for band identification, each probe Crystal identification by light microscopy with or without polarizing lens analysis, any body fluid (except urine) 1984 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 Payment established for each CPT code based on 60% of median 1984 charge 4.1% increase in all fees National limitations (caps) established at 115% of median payment 5·4% increase in all fees Caps reduced to 100% of median. Payment for frequently used tests reduced by 8.3% 4% increase in all fees 4·7% increase in all fees Caps reduced to 93% of median 2% increase in all fees Caps reduced to 88% of median 2% increase in all fees 2% increase in all fees Caps reduced to 84% of median Caps reduced to 80% of median 2·7% increase in all fees Caps reduced to 76% of median 2·6% increase in all fees Caps reduced to 74% of median (2,63% decrease)
Published with permission.' CPT = current procedural terminology. chemistry analysers, specifically the composition of test profiles. The HCFA also stipulated that for certain laboratory tests reimbursement would be made only if a patient had one of certain specified diseases. To justify any of these tests the physician or surgeon must include the appropriate ICD-9-CM code (see glossary) with the test request. If the appropriate code is not included the laboratory will not be reimbursed for performing the test. The government first established a national list of 22 chemistry tests that could be billed as a profile. Subsequently, Medicare decreed that it would no longer pay for tests formerly included in a profile unless each test was individually ordered, i.e., a separate tick mark had to be made for each of the required tests on the requisition form.
While the specific analyser is never mentioned in HCFA documents, the HCFA's statements always referenced high-volume automated chemistry analysers and were targeted at older physicians who received 20 test results automatically when they ordered a single test performed on a Technicon SMAC® (Bayer, Tarrytown NY, USA). The HCFA reasoned that ticking a request for an individual test indicated that a physician thought the test was medically necessary, whereas ticking a request for a profile that included that test did not necessarily demonstrate the clinical justification of the other tests in that profile. Previously, the HCFA would reimburse for a profile if three or more of the tests could be demonstrated to be medically necessary. This change in policy took Ann Clin Biochem 1999: 36 effect for independent, non-hospital-based laboratories in March, 1996 and for hospital laboratories in October, 1996. The HCFA subsequently denied reimbursements for profiles until 1998 when it authorized payment for certain HCFA-specified panels of tests that can be performed on high-volume automated equipment (see below).
MEDICAL NECESSITY
The HCFA has always taken the position that it will not pay for tests used to screen for the presence of disease in asymptomatic patients, thus requiring a physician to have established a probable diagnosis before any test should be ordered. The HCFA also requires that a test, to be justified, should provide additional information beyond that obtained from the clinical history and physical examination. The HCFA is concerned that more expensive tests are used in preference to cheaper alternatives and that tests are ordered at a frequency greater than necessary for good management of a patient.
To demonstrate medical necessity, Medicare has required that the diagnosis or diagnoses of the patient are entered on the requisition form by the physician who orders the tests. At the time the bill is submitted to a Medicare carrier for payment each diagnosis must have been translated into an ICD-9-CM code. Computers are then used to match the ICD-9-CM codes for diseases with the CPT codes of individual tests to determine whether the charge for any or all of the tests should be paid, based on Medicare's interpretation of the medical necessity of the performed tests. When Medicare first introduced the requirement of a diagnosis, it inappropriately placed the onus of providing the diagnosis, and ultimately a diagnostic code, on the laboratory performing the tests. Because of aggressive follow-up by the reference laboratories to which they sent their tests, physicians in private practice became accustomed to providing diagnoses on requests for services, whereas their colleagues in academic medical centres rarely provided diagnoses because the laboratories had little encouragement to obtain the diagnoses. In the hospital setting, the burden on the laboratory of trying to obtain diagnoses became enormous, since it was frequently difficult to reach the ordering physician and created considerable friction between laboratory staff and physicians. Yet without such diagnoses laboratories were at risk of receiving no payment for the services that they provided. Belatedly, Congress recognized its former irrational decision of allocating the responsibility of supplying diagnoses on the laboratory and, beginning in January 1998, assigned that responsibility to the physician caring for the patient. While this does not necessarily ensure that codes will be provided, it does mean that failure to provide the code will no longer be attributable to the laboratory. Nevertheless, laboratories are still expected to verify that the correct ICD-9-CM code has been provided.
Not only has Medicare reserved the right to deny claims for payment of tests without acceptable diagnostic codes, it has identified certain tests which only specific ICD-9-CM diagnostic codes render eligible for reimbursement. These tests are listed in Table 3 . They comprise some of the most frequently requested tests, including those used to evaluate lipid status and thyroid function, glucose levels, prothrombin time, haemoglobin, haematocrit and complete blood counts. Local Medicare carriers determine the appropriate disease indications for specific tests. Thus, there is not uniformity throughout the country. In eastern Pennsylvania there are as few as eight indications for prostatic acid phosphatase but 32 for prostatic specificantigen (PSA). There are as many as 200 indications for prothrombin times, 400 for blood counts, 500 for thyroid function studies and even 600 for carcino-embryonic antigen.
Medicare has developed a list of tests which it believes are experimental or have not demon- strated clinical utility. Some of these are listed in Table 4 . Many clinicians and laboratory staff have accepted the clinical value of several of these tests, such as PSA, yet if a laboratory performs both free and total PSA only the latter is eligible for reimbursement. Medicare does allow laboratories to bill patients directly if they perform any of these tests on them, but it requires a patient to sign an 'Advanced Beneficiary Notice' in which the patient acknowledges that he or she may have to pay personally for the non-covered tests. 
TEST PANELS
Medicare has re-instituted (in 1998) four panels or groupings of automated tests for which it will pay, and has stated that if one of the tests in a panel is deemed to be medically necessary this can justify all the tests in the panel. A single diagnosis, or ICD-9-CM code, suffices for all the tests even though some of the tests might not otherwise qualify as being appropriate. The new panels are listed in Table 5 . Medicare has stipulated that the entire panel must be performed by a clinical laboratory if the group of tests is to be billed as the panel. Many laboratory workers have questioned the logic of some of these panels. Thus, the 'hepatic function panel' requires a laboratory to perform both direct and total bilirubin measurements regardless of the concentration of the total bilirubin. In most laboratories it is established policy not to perform the direct measurement (82251) Numbers in brackets are current procedural terminology (CPT) procedure numbers. unless the total measurement is abnormal. Having to perform the direct bilirubin will add to a clinical laboratory's costs without contributing to good medical practice. Yet if a laboratory does not perform all the tests in a panel Medicare will deny payment for any of the tests in the panel. The 'comprehensive metabolic panel' requires the laboratory to perform an aspartate aminotransferase determination rather than the more appropriate alanine aminotransferase assay as a liver function enzyme. The new panels were devised by representatives of more than 30 clinical professional societies, including the College of American Pathologists, which are affiliated with the American Medical Association, so laboratory staff cannot blame the government for the inappropriateness of some of the tests.
It should be noted that while Medicare was opposed to paying for panels comprising highvolume chemistry tests, it readily accepted the groupings of certain, not exclusively automated, tests into thyroid, lipid and toxoplasma/rubella/ cytomegalovirus/herpes (TORCH) panels and these continued to be payable if only one diagnosis was provided. To receive payment for the panel, the laboratory must perform the tests specified in the panel. In the case of the lipid panel, these are total cholesterol, triglycerides and high-density lipoprotein (HDL)-cholesterol. Medicare does not pay for calculated tests, so a low-density lipoprotein (LDL)-cholesterol test ordered by itself would not qualify for reimbursement unless a direct LDL-cholesterol assay was performed. A calculated LDL-cholesterol result may be provided as part of the lipid panel as long as no charge is made for the calculation. A clinician is not restricted to ordering only the tests in a panel and may order additional tests, e.g., apolipoprotein A or B, if he or she believes they are necessary. Each of these tests must be justified by an appropriate diagnosis.
Medicare has specified certain ordering frequency guidelines. It has decided that ferritin assays should not be performed more frequently than once every 2 months and glycated haemoglobin not more frequently than once every 3 months, except in pregnant women, for whom Medicare has accepted that testing monthly is appropriate. Lipid panel testing should not be performed more frequently than once every 4 months. Although Medicare has not taken a position on carbohydrate antigen (CA) 125 measurements, Aetna (a large health Laboratory services in the USA 129
insurance company) has stated that in a stable patient with prior ovarian cancer it is appropriate to perform the test at a frequency of once every 3 months. Medicare does not pay for certain other laboratory services. These include simple tests such as urinary dipstick measurements and pregnancy tests, which Medicare presumably envisages should be included in the fee for an office visit, and some specific tests such as those involved in assessing the quality of semen, since Medicare does not pay for the treatment of infertility. It also does not pay for multi-allergen radio-allergosorbent tests (RAST) because it considers these to be screening tests.
Medicare has become concerned about overutilization of medical resources, including clinical laboratory tests. While it has not defined what is unnecessary, its reference is the reasonableness and necessity of the tests and services provided. There is likely to be considerable debate as to what these are.
REGULATION
American clinical laboratories are over-burdened with regulations. The laboratory in a major academic medical centre is subject to periodic announced inspections by the Joint Commission on Accreditation of Healthcare Organizations (JCAHO), which accredits hospitals. The JCAHO will either separately accredit the hospital laboratories or accept accreditation by another organization to which it has accorded deemed status, e.g., the College of American Pathologists (CAP). Likewise the local CLIA agency, often the State Department of Health, will accept the deemed status of CAP and JCAHO and not impose a separate inspection. Yet the government reserves the right to re-inspect 5% of all hospitals previously inspected by JCAHO to verify the quality of JCAHO's inspections. Hospitals are licensed by their state, which may also inspect any or all of the hospital's facilities.
The blood bank in a hospital is inspected by the Food and Drug Administration (FDA) to ensure that good manufacturing practices are followed. Many blood banks also undergo voluntary inspections by the American Association of Blood Banks (AABB), and if a hospital provides tissue typing the laboratory will be inspected by the American Society of Histocompatibility and Immunogenetics. A laboratory's proficiency testing results are provided by the With the increasing patenting of assays, reports must be filed quarterly or at least annually with the patent-holders to ensure compliance with the law, and the necessary payments must be made. To meet the requirements of various federal agencies every hospital employee, including laboratory directors, must participate in annual training sessions on biological and chemical safety. Laboratory medical staff must also attend annual Medicare compliance programmes to heighten their awareness of the potential for fraud and illegal practices.
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CONCLUSION
Is it any wonder that the USA manages to spend 13·6% of its GNP on health services, 3% more than any other country? Table 6 lists the home page addresses of several of the organizations involved in clinical laboratory testing in the USA. These web sites provide additional information for the reader who wishes to explore further the intricacies of the US health care system.
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GLOSSARY Capitation
Refers to a method of payment in which a fixed amount is paid each month to the provider (e.g., a physician, a laboratory or a hospital) by an insurance company or other organization. The amount paid is based on the number of persons enrolled in the programme, regardless of the services provided. No additional payment is made when a service is actually provided.
CLIA-88
Clinical Laboratory Improvement Act Amendment of 1988.
Co-insurance
A provision of some medical insurance policies which requires the insured to share a proportion of hospital or medical expenses.
Co-payment A fixed, nominal amount paid by some HMO enrollees for specific services (e.g., $10 for each office visit).
CPT
Physician's Current Procedural Terminology. This is a standardized mechanism of reporting medical services. It uses numerical codes established by the American Medical Association. These are known as CPT codes.
Deductible
Amount required to be paid by the insured before benefits become payable. (e.g., each calendar year, the first $250 of laboratory expenses might be the responsibility of the patient).
Diagnosis-related group (DRG)
A classification scheme for hospital in-patients by which the patient's medical disorder is clustered into one of 468 categories. The DRG is used by the HCFA (see below) to determine the level of payment for hospital care.
Fee-for-service A specific payment for individual services provided.
Gatekeeper A physician, usually a primary care practitioner, who oversees and co-ordinates all aspects of a patient's care. The gatekeeper usually is required to authorize specialty care and non-emergency hospital care. A gatekeeper may also be known as a Care Coordinator.
HCFA
Health Care Financing Administration. The federal government agency that administers the Medicare, Medicaid and Child Health Insurance programs.
Health Maintenance Organization (HMO) An organization that offers comprehensive health coverage for physician and hospital care regardless of the cost of providing the service. An HMO contracts with physicians, hospitals, laboratories and other health care providers to Laboratory services in the USA 131 provide specified services. The patients are enrolled for a fixed period of time and are required to use the specified participating providers. The fee may be paid by the subscriber or an employer.
ICD-9-CM International Classification of Diseases, Ninth Edition, Clinical Modification. Consists of three volumes, the first two contain a tabular listing of diseases organized alphabetically and by body system. ICD-9-CM codes must be provided by physicians to justify the tests they order on outpatients. The third volume contains procedure codes, but the third volume is not to be used by physicians, as they are expected to report procedures using CPT (Physician's Current Procedural Terminology) codes.
Medicaid
Medicaid is the federal health insurance programme for certain poor individuals and their children. The program is jointly administered by the individual states.
Medicare
Medicare is the federal government programme that provides health insurance for people aged over 65 years, and for those suffering specified clinical conditions.
Medicare carrier A company that processes the claims for services by physicians and medical suppliers for Medicare.
Medicare intermediary A company that processes claims for Medicare Part A services and Part B outpatient services.
Part A and Part B The two parts of the Medicare Plan. Part A is hospital insurance. It includes medically necessary services and supplies provided by the hospital, including inpatient laboratory tests, X-rays, semi-private room, meals, nursing care, operating and recovery rooms, intensive care and inpatient prescription drugs. Part B, also known as Supplemental Medical Insurance, pays for services provided by physicians and surgeons both in hospitals and non-hospital settings. It also covers other services such as ambulance transport, certain medical equipment, outpatient hospital and clinical laboratory services, blood products, and physical and speech therapy.
Participating provider A licensed health care provider who has contracted with an insurer to provide care to the program's enrollees.
Pre-certification
A process by which the patient must notify and receive approval for specific outpatient specialty services and elective inpatient admissions (see Gatekeeper).
Prospective payment system A system of fixed reimbursement, usually based on a DRG, set by the government or an HMO before services to the patient are rendered. The efficiency of the provider will determine whether A"" eli" Biochem 1999: 36 it will make a profit or absorb a loss as a consequence of caring for the patient.
Primary care Refers to ambulatory general health care rendered by general practitioners, family practitioners, internists, obstetricians and paediatri-Clans RBRVS Resource-Based Relative Value Scale. A weighting system to assign units of value to each CPT code for procedures performed by physicians and other providers. It takes into consideration physician skill involved, expenses and the geographic area where the service was provided.
